alexa
Reach Us +1-217-403-9671
The Role Of Patents In Biosimilars And Biobetters | 8156
ISSN: 0975-0851

Journal of Bioequivalence & Bioavailability
Open Access

Like us on:

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

The role of patents in biosimilars and biobetters

International Conference and Exhibition on Biowaivers & Biosimilars

Brian R. Dorn

ScientificTracks Abstracts: J Bioequiv Availab

DOI: 10.4172/0975-0851.S1.002

Abstract
The Biologics Price Competition and Innovation Act (BPCIA) provide an approval pathway for biosimilar products. Within the BPCIA, there is twelve year exclusivity for the originator/reference product. Whereby, the Food and Drug Administration (FDA) will not approve a biosimilar application until 12 years after the approval of the reference product. Although the BPCIA provides a patent litigation scheme to determine infringement by the time of the biosimilar approval, it may not be necessary since the 12 year exclusivity may outlast the patent term, even with patent term extension. However, the twelve year exclusivity does not render biologic patents obsolete. Originator molecules are not afforded any exclusivity from non-biosimilar molecules, e.g., Biobetters. Since the definition of a biosimilar (a highly similar molecule) is still being defined by the FDA, and may also continue to evolve with time, variations to the originator molecule may or may not be encompassed by the BPCIA exclusivity period. This session will evaluate what is and is not protected under the current regulatory pathway and the patent landscape.
Biography
Brian R. Dorn, Ph.D., is a patent attorney at Barnes & Thornburg LLP?s Minneapolis office. Dorn has an array of experience in intellectual property with particular emphasis on biotech, pharmaceutical and medical device patent prosecution and opinion work. Dorn?s practice also includes international patenting, where he works with universities, companies, and patent attorneys outside the United States to obtain patents in and outside the United States. Dorn earned his J.D. magna cum laude and his Ph.D. from the University of Florida Colleges of Law and Medicine, respectively, in 2003. Full biography at http://www.btlaw.com/brian-r-dorn/
Top